证券代码：600196 证券简称：复星医药 公告编号：临 2025-173 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | 名称 | 复星医药产业 | | --- | --- | --- | | | 本次担保金额 | 人民币 20,000 万元 | | 被担保方 1 | 截至 2025 年 11 月 6 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 折合人民币 919,116 万元 | | | 是否在前期预计额度内 | 是 □否 □不适用：________ | | | 本次担保是否有反担保 | 被担保方 1 系担保方（本公司）之全 资子公司，不涉及反担保安排 | | 被担保方 | 名称 | 复星安特金 | | | 本次担保金额 | 人民币 30,000 万元 | | 2 | 截至 2025 年 11 月 6 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 人民币 137,607 万元 | | | 是否在 ...

Core Insights - The 8th China International Import Expo (CIIE) opened in Shanghai on November 5, showcasing innovations in the medical device and pharmaceutical sectors under the theme "Healthy China, Beautiful Life" [1] - The medical device and pharmaceutical health exhibition area, known for its high competition, featured global leaders in medical technology and pharmaceuticals, including the top ten medical device companies and 11 Fortune 500 pharmaceutical firms [1] Company Highlights - **Roche**: Displayed over 40 products, including new treatments for Alzheimer's, Parkinson's, and lupus nephritis, with the anti-CD20 monoclonal antibody, Gazyva, and the Port Delivery System (PDS) for eye diseases being key highlights [2][4][5] - **Siemens**: Focused on high-incidence cancers, showcasing advanced technologies like the ARTIS icono ceiling Xpand and the Biograph Vision Quadra PET/CT, aimed at improving diagnostic precision and treatment outcomes [6][7] - **Novartis**: Presented nearly 20 innovative products, including the oral complement factor B inhibitor, Iptacopan, and the radioligand therapy drug, Pluvicto, which received approval for prostate cancer indications [10][12] - **Fosun Pharma**: Introduced the Marie upright particle therapy system, a revolutionary cancer treatment technology, along with advanced non-invasive treatment systems for neurological conditions [12][14] - **Boston Scientific**: Showcased over 80 products in the minimally invasive intervention field, including the Orbera365 gastric balloon system and the Intera3000 hepatic artery infusion pump, with several products making their debut [15][17] - **Novo Nordisk**: Highlighted advancements in diabetes and obesity treatments, including the oral GLP-1 receptor agonist, Rybelsus, and the weekly insulin formulation, IcoSema, which have significantly improved patient convenience [18][20]

（制表：上海上市公司协会） （注：上海证券交易所自2023年起发布科创板上市公司信息披露评价结果；北京证券交易所自2025年起 发布北京证券交易所上市公司信息披露评价结果。） 近期，沪深北交易所陆续公布了上市公司信息披露评价结果。根据《沪市上市公司2024至2025年度信息 披露工作评价结果》、《关于深市上市公司2024-2025年度信息披露工作评价结果的通报》、《关于发 布2024-2025年度北京证券交易所上市公司信息披露工作评价结果的公告》显示，上海辖区89家上市公 司信息披露评价结果获得A，其中沪市主板44家、深市主板4家、创业板12家，科创板25家，北交所4 家。据统计，共有44家上市公司连续三个年度获得信息披露考评结果A，17家上市公司连续五个年度获 得信息披露考评结果A。其中，复星医药（600196）连续五年获上交所信息披露A级评价。 详见下表： ...

Core Insights - The 8th China International Import Expo (CIIE) showcases innovative medical devices and pharmaceuticals from global giants like Novartis, Roche, Pfizer, Siemens Healthineers, and Philips, highlighting the latest advancements in medical technology [1] - Chinese domestic innovation is also significant, with companies like Fosun Pharma and Weisheng Pharma presenting leading-edge products and collaborations, indicating a robust local industry [1][2] - By the first half of 2025, the total amount of overseas licensing for Chinese innovative drugs is projected to reach $60 billion, accounting for 99% of global related transactions [1] Group 1: Innovative Products - Siemens Healthineers showcased a 1,000 square meter exhibit featuring a rapid spectral angiography system capable of detecting small tumors in 2.5 seconds [2] - Novartis presented 11 Galien Award-winning products, emphasizing its strong innovation track record with nearly 80 awards since 1970 [2] - Fosun Pharma displayed advanced products such as the Da Vinci surgical robot and CAR-T cell therapy, demonstrating its commitment to cutting-edge medical technology [2] Group 2: Local Innovation and Market Adaptation - Companies like Zhuhai Respira and Shenzhen Weide are developing innovative solutions tailored to the Chinese market, with rapid development cycles and efficient clinical research [3] - The trend of "localized innovation" is prevalent, with many foreign companies adapting their products to meet local needs, as seen with Carl Zeiss and Varian Medical Systems [4][6] - Philips has established five innovation centers and five manufacturing bases in China, with over 95% of its products developed and manufactured locally [6] Group 3: Foreign Investment and Market Engagement - Foreign companies are increasing investments in China, with plans for new facilities and projects, such as Novartis's radioactive drug production base expected to be operational by the end of 2026 [7] - Medtronic has set up a regional venture capital fund in China, investing in over 10 local medical technology startups to enhance innovation [7] - Companies are also targeting county and grassroots markets in China, with tailored products like fully automated biochemical analyzers designed for local healthcare environments [8]

Core Insights - The 8th China International Import Expo (CIIE) opened on November 5, 2023, in Shanghai, featuring participation from 155 countries and regions, with six countries serving as guest countries [1] - The exhibition area exceeded 430,000 square meters, with 4,108 participating companies, an increase of over 600 from the previous year, including 290 Fortune 500 and industry-leading companies, marking the highest participation to date [1] - CIIE has evolved beyond a mere international procurement platform to become a crucial link in the domestic and international dual circulation [1] Group 1: Company Participation - Schneider Electric, a "full attendance" participant, showcased its R&D achievements under the "China-centric" strategy, presenting new products developed in China [2] - Johnson Controls views CIIE as a strategic platform for its development in China, focusing on digitalization, clean energy, and advanced manufacturing [3] - Fosun Pharma has leveraged CIIE's spillover effects to accelerate the introduction of innovative medical technologies and products into the Chinese market [4][5] Group 2: Innovation and New Products - CIIE serves as a stage for global product launches, with 461 new products, technologies, and services showcased, turning China into a testing ground for global innovation [6] - Honeywell highlighted its 90-year history in China, presenting eight new products, many of which were developed locally [6] - Bayer emphasized CIIE as a strategic platform for integrating into China's economic development, showcasing 26 highlighted products, including five global debuts [7] Group 3: Market Impact - The cumulative intended transaction amount from the first seven CIIEs exceeded $500 billion, reflecting its growing influence and scale [8] - CIIE is a vivid representation of China's open stance towards the world, providing a broad platform for global companies to share opportunities and collaborate on development [8]

Core Insights - The eighth China International Import Expo (CIIE) showcased several innovative medical devices and healthcare products, attracting significant attention from global trade delegations [1][2] Group 1: Medical Devices - Boston Scientific presented the ENROUTE Transcarotid Artery Revascularization (TCAR) device, the first and only approved device for TCAR procedures, aimed at reducing intraoperative risks associated with carotid artery stenosis [1] - Another product from Boston Scientific, the FARAWAVE NAV catheter, utilizes non-thermal electric fields for cardiac tissue ablation and has treated approximately 500,000 patients globally [1] - Medtronic introduced the Inceptiv closed-loop rechargeable spinal nerve stimulation system, designed to improve the quality of life for patients with chronic pain through weak electrical stimulation [4] - BD Medical showcased the M.R.I™ 4F Slim Implantable Port, the thinnest catheter in its category, designed for the Chinese population, which significantly reduces thrombosis rates by 40% [4] - The Venclose™ catheter, designed for treating lower limb varicose veins, features a flexible setup that minimizes patient trauma [5] Group 2: Innovative Treatments - Fosun Pharma presented the Exablate Neuro system, a high-intensity focused ultrasound (HIFU) device combined with MRI for treating drug-resistant essential tremors and Parkinson's disease [6] - Eli Lilly introduced innovative drugs targeting aging and obesity, including donanemab for Alzheimer's disease, which has shown to delay disease progression by approximately 30% in clinical trials [6]

Core Insights - The China International Import Expo (CIIE) showcases innovative products across various sectors, including healthcare and automotive, with a record participation of 155 countries and over 4,108 foreign enterprises [1][2] Product Highlights - Notable medical products include the Ferghana needleless intravenous catheter, which reduces the risk of needle-stick injuries, and the 3DMax hernia repair patch, designed for quick deployment and reduced postoperative pain [2] - The Marie particle therapy system by Fosun Pharma represents a revolutionary advancement in cancer treatment, offering a cost-effective and space-saving alternative to traditional systems [2] - Tesla's Cybercab, an autonomous electric vehicle, features a streamlined design without a steering wheel or pedals, utilizing a vision processing system for self-driving capabilities [3] Market Entry and Transformation - The CIIE serves as a platform for global medical technology companies to convert exhibits into market-ready products, with BD Medical reporting that nearly 95% of their showcased products have entered the market [4] - Fosun Pharma has leveraged the CIIE to accelerate the introduction of cutting-edge technologies and innovative medical products into China [4] Investment Opportunities - The CIIE has attracted foreign exhibitors to become investors in China, with BD Medical planning to establish a new innovation center in Tianjin [5] - Tutti Pharmaceuticals, which successfully entered the Chinese market last year, is now considering building a factory in China to enhance its research and development capabilities [6]

Core Insights - The China International Import Expo (CIIE) showcases innovative products across various sectors, including healthcare and automotive, with a record participation of 155 countries and over 4,108 foreign enterprises [1][2] Group 1: Product Highlights - The expo features groundbreaking medical products such as the needle-free intravenous catheter by BD Medical, which reduces the risk of needle-stick injuries and enhances safety for healthcare workers [2] - Fosun Pharma presents the Marie vertical particle therapy system, a revolutionary approach in cancer treatment that offers a cost-effective and space-saving alternative to traditional systems [2] - Tesla's Cybercab, an autonomous electric vehicle, makes its Asia-Pacific debut, utilizing a vision processing system and neural network for self-driving capabilities without expensive hardware [3] Group 2: Market Entry and Transformation - The CIIE serves as a platform for foreign companies to accelerate their entry into the Chinese market, with BD Medical reporting that nearly 95% of its showcased products have transitioned into commercial products [4] - Fosun Pharma has leveraged the expo's influence to introduce several advanced technologies and innovative medical products into China, enhancing the country's healthcare system [4] Group 3: Investment Opportunities - The expo not only facilitates product entry but also attracts exhibitors to become investors in China, as highlighted by BD Medical's plans to establish a new innovation center in Tianjin [5][6] - Companies like Tutti Pharmaceuticals have successfully entered the Chinese market through the expo and are now considering local manufacturing due to favorable conditions for research and development [6]

Core Insights - The China International Import Expo (CIIE) showcases innovative products across various sectors, including healthcare and automotive, with a record participation of 155 countries and over 4,108 foreign enterprises [1][2] - The event serves as a platform for global companies to introduce their products to the Chinese market, facilitating the transformation of exhibits into commercial products [3][4] Healthcare Innovations - BD Medical introduced the Ferghana needle-free intravenous catheter and the 3DMax hernia repair patch, which enhance safety and efficiency in medical procedures [1] - Fosun Pharma presented the Marie upright particle therapy system, offering a cost-effective and space-saving alternative to traditional radiation therapy systems [2] Market Entry and Product Commercialization - BD Medical reported that nearly 95% of its showcased products have been commercialized, accelerating the entry of its products into Chinese hospitals [3] - The CIIE has enabled companies like Fosun Pharma to successfully launch advanced technologies and innovative medical products in China [3] Investment Opportunities - The CIIE has attracted exhibitors to become investors, with BD Medical planning to establish a new innovation center in Tianjin [4] - Companies like Tutti Pharma have successfully entered the Chinese market through the CIIE and are now considering local manufacturing due to favorable conditions [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600196 证券简称：复星医药公告编号：临2025-170 上海复星医药（集团）股份有限公司 第十届董事会第十四次会议（临时会议） 决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"）第十届董事会第十四次会议（临时会议）于 2025年11月4日召开，全体董事以通讯方式出席了会议。本次会议的召开符合《中华人民共和国公司 法》、其他有关法律法规和《上海复星医药（集团）股份有限公司章程》的规定。会议审议并达成如下 决议： 一、审议通过关于2025年A股股票期权激励计划首次授予相关事项的议案。 1、根据本公司2025年第一次临时股东会（以下简称"股东会"）已审议通过之《上海复星医药（集团） 股份有限公司2025年A股股票期权激励计划》（以下简称"2025年A股期权计划"）及相关授权，鉴于该 计划下首次授予拟激励对象中的6名已不在本集团（即本公司及控股子公司/单位，下同）任职、不再属 于该计划的激励对象范围，董事会同 ...